

INVITATION TO PRESENTATION OF OREXO'S Q1 2025 INTERIM REPORT

Uppsala, Sweden – April 25, 2025 – As previously communicated Orexo will announce the Interim Report for the first quarter of 2025 on May 6 at 8 am CEST.

The same day at 2 pm CEST, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järsten, CFO, will present the latest development and host a Q&A.

To attend via teleconference where you can ask questions verbally use this link:

<https://events.inderes.com/orexo/q1-report-2025/dial-in>

When registered you will be provided phone numbers and a conference ID to access the conference.

To attend via webcast:

<https://orexo.events.inderes.com/q1-report-2025>

Prior to the event the presentation material will be available on the website under Investors /Report Archive

For further information, please contact:

Orexo AB (publ.)

Lena Wange, IR & Communications Director

Tel: +46 (0) 18 780 88 00

Email: ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX market (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

Attachments

[Invitation to presentation of Orexo's Q1 2025 Interim Report](#)